TMCnet News
Summit Appoints Valerie Andrews as a Non-Executive Director(dpa-AFX International Compact Via Acquire Media NewsEdge) Summit Corporation plc ('Summit' or 'the Company') SUMMIT APPOINTS VALERIE ANDREWS AS A NON-EXECUTIVE DIRECTOR Oxford, UK, 19 September 2014 - Summit (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), announces the appointment of Ms Valerie Andrews as a Non-Executive Director. "Valerie Andrews has a broad range of commercial and legal skills from her career within the healthcare and life sciences industry and, on behalf of Summit, I am very pleased to welcome her to the Board of Directors," commented Dr Frank Armstrong, Non-Executive Chairman of Summit. "We have seen a number of recent corporate developments across the Company, including the expansion of our operations into the US, o support advancement of our DMD and CDI programmes. With her background in the industry, Valerie's input and expertise will prove invaluable in supporting the continued growth of the Company." Valerie Andrews added, "I am delighted to be joining Summit at this exciting stage in its development as its two innovative programmes for the treatment of DMD and CDI progress through patient clinical trials. I look forward to working with the experienced leadership team at the Company as we aim to establish the clinical benefit of these potential life-changing treatments." About Ms Valerie Andrews (aged 55) Ms Valerie Andrews has extensive skills in business and legal matters related to the healthcare industry having held executive and non-executive roles within publically listed biotechnology companies, major hospitals and in legal practice. Ms Andrews has a range of expertise across a number of areas including strategic transactions, corporate governance, risk management and compliance. Ms Andrews served as the General Counsel for Vertex Pharmaceuticals Inc until May 2014. Prior to joining Vertex in 2002, she was an Executive Director of Licensing for Massachusetts General and The Brigham and Women's Hospitals in Boston, and a partner in the Boston law firm Hill & Barlow. She served as a law clerk to the Chief Judge Levin H Campbell of the US Court of Appeals for the First Circuit from 1988 to 1989. Ms Andrews has also been a Non-Executive Director of the drug development company Columbia Laboratories since 2005. Ms Andrews is a member of the Massachusetts Bar, and holds a JD in law (Boston College) and a BA in chemistry and psychology (Duke University). Ms Andrews has notified the Company of the following: +--------------------------------------+---------------------------------------+ |Current Directorships and Partnerships|Directorships and Partnerships (past 5 | | |years) | +--------------------------------------+---------------------------------------+ |Columbia Laboratories, Inc |None | +--------------------------------------+---------------------------------------+ The Company confirms there is no other information required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules. - END - Notes to Editors About Summit Summit is a drug discovery and development company targeting two high-value areas of unmet medical need: the muscle wasting disease Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc). For more information, please contact: Summit Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski (US office) +1 617 294 6607 Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson Tel: +44 (0)20 7148 7900 N+1 Singer (Broker) Aubrey Powell / Jen Boorer Tel: +44 (0)20 7496 3000 Peckwater PR (Financial public relations, UK) Tel: +44 (0)7879 458 364 Tarquin Edwards [email protected] MacDougall Biomedical Communications (US media contact) Michelle Avery Tel: +1 781 235 3060 [email protected] Forward Looking Statements This announcement contains "forward-looking statements", including, but not limited to, statements about the discovery, development and commercialisation of programme assets. These forward-looking statements are statements based on the Company's current intentions, beliefs and expectations, which include, among other things, the Company's results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. No forward-looking statement is a guarantee of future performance and actual results could differ materially from those expressed or implied in the forward- looking statements. Accordingly, readers should not place undue reliance on forward-looking statements or information. Forward-looking statements and information by their nature involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These include but are not limited to: adverse results in clinical or preclinical development studies; delays in obtaining regulatory approval; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; being unable to secure partnership agreements to develop and commercialise programme assets; being unable to secure the necessary funding to conduct any proposed research and development studies; and the ability to retain and recruit key personnel. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this announcement to reflect any changes in expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based, except as required by applicable law. This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Corporation PLC via GlobeNewswire [HUG#1856944] A0DKWDBN40HZ0R41 Copyright RTT News/dpa-AFX |